CERENIA INJECTABLE SOLUTION

Antiemetic

Cerenia (maropitant citrate) Injectable Solution is indicated for the prevention and treatment of acute vomiting in dogs and cats. Maropitant citrate acts by blocking vomiting signals to the brain to prevent vomiting.

Dosage and Administration: Administer CERENIA Injectable Solution subcutaneously at 1.0 mg/kg (0.45 mg/lb) equal to 1.0 mL/10 kg (1.0 mL/22 lb) of body weight once daily for up to 5 consecutive days.

For subcutaneous injection in dogs and cats only

CERENIA Injectable Solution is recommended for use in dogs and cats 16 weeks and older.

CERENIA Injectable Solution may be used interchangeably with CERENIA Tablets for once daily dosing for the prevention of acute vomiting.

Warnings: Not for use in humans. Keep out of reach of children. In case of accidental injection or exposure, seek medical advice. Topical exposure may elicit localized allergic skin reactions in some individuals. Repeated or prolonged exposure may lead to skin sensitization. In case of accidental skin exposure, wash with soap and water. CERENIA is also an ocular irritant. In case of accidental eye exposure, flush with water for 15 minutes and seek medical attention.

In puppies younger than 11 weeks of age, histological evidence of bone marrow hypoplasia was seen at higher frequency and greater severity in puppies treated with CERENIA than in control puppies. In puppies 16 weeks and older, bone marrow hypoplasia was not seen (See Animal Safety Section).

Precautions: For subcutaneous injection only. The safe use of CERENIA has not been evaluated in dogs used for breeding, pregnant or lactating bitches, dogs with gastrointestinal obstruction, or dogs that have ingested toxins. Use with caution in dogs with hepatic dysfunction. Use with caution with other medications that are highly protein bound. The concomitant use of CERENIA with other protein bound drugs has not been studied in dogs. Commonly used protein bound drugs include NSAIDs, cardiac, anticonvulsant and behavioral medications. The influence of concomitant drugs that may inhibit metabolism of CERENIA has not been evaluated. Drug compatibility should be monitored in patients requiring adjunctive therapy.